Guidelines for Switching from Invega Sustenna to Caplyta

Introduction to Switching Protocol

• When switching from Invega Sustenna to Caplyta, a gradual cross-titration approach should be used, informed by the half-life and receptor profile of each medication, as recommended by The Lancet Psychiatry 1

Switching Considerations

• Begin Caplyta administration when the next scheduled Invega Sustenna injection would have been due to minimize the risk of withdrawal symptoms or rebound psychosis, according to The Lancet Psychiatry 1
• For patients on higher doses of Invega Sustenna, consider starting Caplyta slightly earlier (1-2 weeks before the next scheduled injection) to ensure adequate coverage, as suggested by The Lancet Psychiatry 1
• Monitor closely for the first 4 weeks during the transition period, as advised by The Lancet Psychiatry 1
• Assess therapeutic response after at least 4 weeks on Caplyta, as recommended by The Lancet Psychiatry 1
• Monitor for emergence of positive symptoms, which may indicate inadequate treatment coverage, according to The Lancet Psychiatry 1
• Avoid abrupt discontinuation of Invega Sustenna without implementing Caplyta, as this increases risk of relapse, as warned by The Lancet Psychiatry 1
• Monitor for potential drug interactions, particularly those affecting metabolism, as cautioned by The Lancet Psychiatry 1
• Ensure the patient understands the transition from a monthly injection to daily oral medication, as this may impact adherence, as noted by The Lancet Psychiatry 1
• Confirm diagnosis and current symptom control on Invega Sustenna before switching, as recommended by The Lancet Psychiatry 1
• Monitor closely for 4 weeks to ensure adequate symptom control after switching, as advised by The Lancet Psychiatry 1
• The switch to Caplyta may offer improved tolerability and eliminate the need for injections, which some patients may prefer, as reported by The Lancet Psychiatry 1
• Antipsychotic switching should involve shared decision-making with the patient, considering both efficacy and side-effect profiles, as recommended by The Lancet Psychiatry 1